Medtronic's MiniMed Swap Nears Pricing Window as Cardiac Franchise Racks Up Clearances

Medtronic's MiniMed exchange offer pricing runs Oct. 5-7 and closes Oct. 9, as its heart unit adds FDA and CE clearances and new CPT codes.

Medtronic is entering a defining stretch for its corporate makeover, with the mechanics of its MiniMed separation moving into the home straight just as its cardiovascular business collects a fresh batch of regulatory wins.

The diabetes-care carve-out, set in motion roughly three weeks ago, has been a drag on the stock since its announcement, with the shares shedding 2.2% over that span. Attention now turns to the formal timetable governing the exchange offer. According to the Nasdaq, a three-day pricing period for the MiniMed share swap kicks off on Oct. 5 and runs through Oct. 7. The offer itself is scheduled to close at midnight New York time on Oct. 9, unless it is extended or terminated early.

The transaction is designed to streamline the group's structure and free up resources for higher-margin segments, sharpening the focus on research and product launches where Medtronic sees the strongest synergies with its core device business. For investors, the expiry of the exchange offer marks a key waypoint in that restructuring. Based on current market pricing, the group carries a market capitalization equivalent to EUR 97.94 billion.

Regulatory Momentum Across the Heart Portfolio

Running alongside the portfolio surgery, Medtronic notched progress on both sides of the Atlantic in its cardiac operations. The Affera Prism-2 mapping software secured clearance from the US Food and Drug Administration as well as the European CE mark. The company also picked up CE certification for its PulseSelect ProxBox adapter, which pairs with software designed to detect spacing — a combination that reinforces its hand in systems used for cardiovascular procedures.

In peripheral vascular disease, Medtronic is pushing new clinical evidence forward. Having previously won FDA Breakthrough Device designation for its drug-coated IN.PACT BTK balloon catheter, the company is preparing a randomized pivotal trial. The study is expected to enroll around 400 patients and is intended to build out the clinical case for the system.

Reimbursement Codes Set the Stage Through 2028

Beyond product approvals, the billing infrastructure that underpins adoption in the US healthcare system delivered its own victory. New Category I CPT reimbursement codes were granted for the Altaviva tibial neuromodulation system, used to treat urge incontinence, and for the Symplicity Spyral renal denervation system targeting high blood pressure.

Issued by the American Medical Association, the codes replace the previous Category III transitional designations. They take effect in January 2028 and, according to the company, recognize both the clinical evidence and the growing acceptance of the two therapies among specialists — effectively mapping out the payment framework for these treatments in the US market for years to come.

Setbacks Temper the Advance

Not everything has gone Medtronic's way. Roughly three weeks ago, the FDA slapped its most serious Class I designation on the recall of certain Bravo CF capsule systems used to monitor esophageal pH. The stock has lost 5.6% since that action. In connection with the matter, the company had reported 184 serious injury cases and no deaths in August.

There was also movement at the top. Harry "Skip" Kiil, Executive Vice President and President of Cardiovascular, parted with 1,483 common shares on Sept. 16, according to regulatory filings. The disposal was executed at USD 93.65 per share.

Market Backdrop

Investors have kept their distance of late. The stock closed Friday's session at EUR 76.72, a decline of 0.3% on the day, leaving it down 3.6% over a 30-day window.